Natixis’s Axsome Therapeutics AXSM Stock Holding History

Natixis’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$136K	Buy	555 +254	+84%	+$55.1K	﹤0.01%	974
2026 Q1	$50.9K	Buy	+301	New	+$52K	﹤0.01%	982
2025 Q4	–	Sell	-485	Closed	-$58.9K	–	1129
2025 Q3	$58.9K	Hold	485	–	–	﹤0.01%	927
2025 Q2	$50.6K	Buy	+485	New	+$51.4K	﹤0.01%	880
2025 Q1	–	Sell	-748	Closed	-$63.3K	–	985
2024 Q4	$63.3K	Sell	748 -142	-16%	-$13.1K	﹤0.01%	870
2024 Q3	$80K	Sell	890 -32,762	-97%	-$2.86M	﹤0.01%	762
2024 Q2	$2.71M	Buy	33,652 +32,417	+2,625%	+$2.4M	0.02%	368
2024 Q1	$98.6K	Buy	1,235 +148	+14%	+$12.4K	﹤0.01%	777
2023 Q4	$86.5K	Sell	1,087 -57	-5%	-$3.81K	﹤0.01%	787
2023 Q3	$80K	Buy	+1,144	New	+$85.5K	﹤0.01%	799

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Natixis's AXSM Position: Q2 2026 in Review

Natixis increased its Axsome Therapeutics (AXSM) stake by 84% in Q2 2026, buying an estimated $55.1K and bringing the position to 555 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Natixis first reported a position in AXSM in Q3 2023 and has held it in 10 quarters since. The position peaked at $2.71M in Q2 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Natixis held 555 shares of Axsome Therapeutics worth $136K as of Q2 2026.
Natixis bought 254 Axsome Therapeutics shares in Q2 2026, an estimated $55.1K.
Axsome Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #974 holding.
Natixis first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 10 quarters since.
Natixis's Axsome Therapeutics position peaked at $2.71M in Q2 2024.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.